303 related articles for article (PubMed ID: 26288480)
1. Dual inhibition of acetylcholinesterase and butyrylcholinesterase enzymes by allicin.
Kumar S
Indian J Pharmacol; 2015; 47(4):444-6. PubMed ID: 26288480
[TBL] [Abstract][Full Text] [Related]
2. In vitro anti-beta-secretase and dual anti-cholinesterase activities of Camellia sinensis L. (tea) relevant to treatment of dementia.
Okello EJ; Savelev SU; Perry EK
Phytother Res; 2004 Aug; 18(8):624-7. PubMed ID: 15476306
[TBL] [Abstract][Full Text] [Related]
3. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
4. IN VITRO ACETYLCHOLINESTERASE AND BUTYRYLCHOLINESTERASE INHIBITORY POTENTIALS OF JATROPHA GOSSYPIFOLIA PLANT EXTRACTS.
Saleem H; Ahmad I; Shahid MN; Gill MS; Nadeem MF; Mahmood W; Rashid I
Acta Pol Pharm; 2016; 73(2):419-23. PubMed ID: 27180434
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
6. Anticholinesterase and Antioxidant Activities of Natural Abietane Diterpenoids with Molecular Docking Studies.
Topçu G; Akdemir A; Kolak U; Öztürk M; Boğa M; Bahadori F; Çakmar SDH
Curr Alzheimer Res; 2020; 17(3):269-284. PubMed ID: 32329687
[TBL] [Abstract][Full Text] [Related]
7. Lepidine B from Lepidium sativum Seeds as Multi-Functional Anti- Alzheimer's Disease Agent: In Vitro and In Silico Studies.
Talia S; Benarous K; Lamrani M; Yousfi M
Curr Comput Aided Drug Des; 2021; 17(3):360-377. PubMed ID: 32116197
[TBL] [Abstract][Full Text] [Related]
8. Screening of traditional European herbal medicines for acetylcholinesterase and butyrylcholinesterase inhibitory activity.
Wszelaki N; Kuciun A; Kiss AK
Acta Pharm; 2010 Mar; 60(1):119-28. PubMed ID: 20228046
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and molecular docking studies of some 4-phthalimidobenzenesulfonamide derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors.
Soyer Z; Uysal S; Parlar S; Tarikogullari Dogan AH; Alptuzun V
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):13-19. PubMed ID: 27766908
[TBL] [Abstract][Full Text] [Related]
10. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
[TBL] [Abstract][Full Text] [Related]
11. Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones.
Piazzi L; Belluti F; Bisi A; Gobbi S; Rizzo S; Bartolini M; Andrisano V; Recanatini M; Rampa A
Bioorg Med Chem; 2007 Jan; 15(1):575-85. PubMed ID: 17008100
[TBL] [Abstract][Full Text] [Related]
12. Acetylcholinesterase and butyrylcholinesterase inhibition by nectriapyrone and tryptophol isolated from endophytic fungus
Dos Santos R; Morais-Urano RP; Marçal RM; Silva GH; Santos MFC
Nat Prod Res; 2022 Aug; 36(16):4153-4158. PubMed ID: 34498969
[TBL] [Abstract][Full Text] [Related]
13. Species- and concentration-dependent differences of acetyl- and butyrylcholinesterase sensitivity to physostigmine and neostigmine.
Bitzinger DI; Gruber M; Tümmler S; Michels B; Bundscherer A; Hopf S; Trabold B; Graf BM; Zausig YA
Neuropharmacology; 2016 Oct; 109():1-6. PubMed ID: 26772968
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses.
Kamal MA; Shakil S; Nawaz MS; Yu QS; Tweedie D; Tan Y; Qu X; Greig NH
CNS Neurol Disord Drug Targets; 2017; 16(7):820-827. PubMed ID: 28176640
[TBL] [Abstract][Full Text] [Related]
15. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA
Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845
[TBL] [Abstract][Full Text] [Related]
16. 1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BuChE, and amyloid-β aggregation crossing the blood-brain barrier.
Prinz M; Parlar S; Bayraktar G; Alptüzün V; Erciyas E; Fallarero A; Karlsson D; Vuorela P; Burek M; Förster C; Turunc E; Armagan G; Yalcin A; Schiller C; Leuner K; Krug M; Sotriffer CA; Holzgrabe U
Eur J Pharm Sci; 2013 Jul; 49(4):603-13. PubMed ID: 23643737
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
[TBL] [Abstract][Full Text] [Related]
18. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Greig NH; Lahiri DK; Sambamurti K
Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181
[TBL] [Abstract][Full Text] [Related]
19. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
Eskander MF; Nagykery NG; Leung EY; Khelghati B; Geula C
Brain Res; 2005 Oct; 1060(1-2):144-52. PubMed ID: 16212945
[TBL] [Abstract][Full Text] [Related]
20. Cholinesterase inhibitors: new roles and therapeutic alternatives.
Giacobini E
Pharmacol Res; 2004 Oct; 50(4):433-40. PubMed ID: 15304240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
